RecruitingNot ApplicableNCT06963047

Evaluation of Blood Loss After Cesarean Delivery Via US Compared to Standard Care

Ultrasound Use Compared With Standard Care for Diagnosis of Blood Loss After Cesarean Delivery: A Randomized Controlled Trial


Sponsor

Holy Family Hospital, Nazareth, Israel

Enrollment

276 participants

Start Date

May 8, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Postpartum hemorrhage and anemia are considered a major health concern due to their impact on maternal morbidity and mortality, quality of life, and maternal cognitive and emotional functioning after delivery, which are particularly important during the critical period of mother-child bonding. Hemoglobin levels in the first 24 hours after delivery do not reflect the lowest point (nadir). The postpartum nadir occurs 48-72 hours after delivery due to the initial redistribution of plasma volume. The aim of this study was to examine whether postpartum ultrasound examination precedes laboratory test results in the diagnosis of anemia due to blood loss after cesarean section.


Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 50 Years

Inclusion Criteria4

  • Women who delivered by a cesarean section.
  • Age over 18.
  • Fluent in Hebrew or Arabic.
  • Signed informed consent form.

Exclusion Criteria4

  • Lack of consent or inability to provide informed consent.
  • Inability to perform a post-surgical ultrasound, such as post-surgery hospitalization in the intensive care unit.
  • Women with preoperative coagulation disorders.
  • Women whose clinical condition requires a post-cesarean ultrasound examination.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTUltrasound

The purpose of the test is to diagnose and assess the amount of blood loss.

OTHERStandard care

Routine management


Locations(1)

Holy family hospital

Nazareth, North, Israel

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06963047


Related Trials